Skip to main content

ISC24: ecco la lista delle Late Breaking Science Sessions

Redazione By 5 Febbraio 2024Febbraio 6th, 2024No Comments
Dai congressiNewsSpeciali

Si terrà dal 7 al 9 febbraio a Phoenix (Arizona) l’edizione 2024 dell’International Stroke Conference (ISC24), uno degli eventi più importanti al mondo nell’ambito della ricerca sulle patologie cerebrovascolari e, in generale, la salute del cervello. Riportiamo di seguito l’elenco degli studi che saranno presentati nel corso delle Late Breaking Science Sessions previste nel corso delle tre giornate congressuali:

Late-Breaking Science Main Event Sessions

Mercoledì 7 febbraio:

  • ZODIAC: Zero Degree Head Positioning in Acute Large Vessel Ischemic Stroke
  • RESILIENT-Extend: Randomization of Endovascular Treatment with Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke due to Large VEssel OcclusioN Trial in the Extended Time Window
  • MOST. Multi-Arm Optimization of Stroke Thrombolysis Trial

Giovedì 8 febbraio:

  • TREND: Intravenous Tirofiban Reduces Early Neurological Deterioration in Acute Ischemic Stroke: The Trend Randomized Controlled Clinical Trial
  • Uric Acid Supplementation Provides Cerebroprotection Across Different Animal Species, Sex, Age and Comorbidities: A Report From the Stroke Preclinical Assessment Network (SPAN)
  • Rescue on Reperfusion Damage in Cerebral Infarction by Nelonemdaz: A Phase III Trial
  • Golden Bridge II: Effect of an Artificial Intelligence-Based Clinical Decision Support System on Stroke Care Quality and Outcomes in Patients With Acute Ischemic Stroke : A Cluster-Randomized Clinical Trial

Venerdì 9 febbraio:

  • EMBOLISE: Embolization of the Middle Meningeal Artery With OnyxTM Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma
  • MAGIC-MT: The MAGIC-MT Trial: Managing Non-Acute Subdural Hematoma Using Liquid Materials: A Chinese Randomized Trial of Middle Meningeal Artery Treatment
  • STOP-CAD: Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study
  • STEM: STEM (The Squid Trial for the Embolization of the MMA for the treatment of CSDH)
  • Delayed Therapy With Humanized Anti-Sdc2 mAb Prevents Formation of Vasogenic Edema and Promotes Neuroprotection in Non-Human Primates With Ischemic Stroke
  • CHABLIS-II: Tenecteplase Thrombolysis for Stroke Up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial
  • Machine Learning Algorithms for Autonomous Detection of Stroke Symptoms and Bell’s Palsy
  • RAISE: Reteplase Treating Patients With Acute Ischemic Stroke (RAISE): A Phase 3, Multi-Centre, Open-Label, Randomised Controlled, Non-Inferiority Trial
  • INSPIRES: Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke or Transient Ischemic Attack: The INSPIRES Randomized Clinical Trial
  • SELECT2: Long-Term Outcomes and EVT Treatment Effect From Randomized Controlled Trial of Endovascular Thrombectomy for Large Ischemic Strokes
Late Breaking Science Concurrent Oral Abstract Sessions

Mercoledì 7 febbraio:

Late Breaking Science Oral Abstracts I

  • TESLA: The Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke Trial: 1-Year Outcome
  • Twin2Win: A Randomized Study to Compare the Efficacy of Primary Dual-Stent Retriever vs. Primary Single-Stent Retriever Technique
  • RESCUE: A Randomized, Blinded Placebo-controlled, Parallel Group Trial to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
  • A Novel Artificial Intelligence Method to Measure Functional Outcomes in Rodents: A Report From the Stroke Preclinical Assessment Network (SPAN)

Late Breaking Science Oral Abstracts II

  • Outcomes of Patients With Endovascular Thrombectomy in the Multi-Arm Optimization of Stroke Thrombolysis Trial
  • Subgroup Analysis of Fasudil Efficacy in the Multi-Laboratory Stroke Preclinical Assessment Network Trial
  • Tenecteplase versus Alteplase for Acute Ischemic Stroke in the Oldest-Old Patients
  • Fibrinogenase for Injection in the Treatment of Acute Ischemic Stroke: A Randomized Double Bline and Placebo Controlled Study

Giovedì 8 febbraio:

Late Breaking Science Oral Abstracts III

  • Infarct Size and Estimated Treatment Effect of Early versus Late Anticoagulation After Ischemic Stroke in People With Atrial Fibrillation
  • ARCADIA: Anticoagulation for Prevention of Silent Infarct in the ARCADIA Trial
  • Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis Triggers Intracerebral Hemorrhage in Mutant KRAS-Induced Brain Arteriovenous Malformations
  • Secondary Analyses to Optimize Response to Andexanet from ANNEXa-1

Late Breaking Science Oral Abstracts IV

  • Lipid Accumulation in Mouse and Human Peripheral Blood Leukocytes After Ischemic Stroke and Its Correlation to Functional Outcome
  • Impact of Stenosis Degree on the Efficacy of Stenting versus Medical Therapy Alone for Symptomatic Intracranial Stenosis: A Preplanned Pooled Analysis of Individual Patient Data
  • INSPIRES: Dual Antiplatelet Therapy in Patients With Multiple Acute Infarctions of Atherosclerotic Origin: A Subgroup Analysis of the INSPIRES Randomized Clinical Trial
  • TIMELESS: Subgroup Analyses From the TIMELESS Trial

Late Breaking Science Oral Abstracts V

  • Impact of COVID-19 Vaccine on Cerebrovascular Health: A Prospective Community-Based Study
  • ARCADIA: Atrial Cardiopathy Biomarkers and Atrial Fibrillation in the ARCADIA Trial
  • Fingolimod as a Potential Cerebroprotectant Results From the Stroke Preclinical Assessment Network (SPAN)
  • MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and First 900 Subjects